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CARD9 is a signaling adaptor protein that is involved in the transduction of signals from 
a variety of innate pattern recognition receptors, including the C-type lectin receptors 
and intracellular NOD receptors and nucleic acid sensors. As a result, CARD9 has 
been shown in animal models to be an important regulator of immunity to bacteria, 
fungi, and viruses. Studies in humans with autosomal recessive CARD9 deficiency have 
indicated a highly specific role for this molecule in the activation of antifungal immune 
responses in the central nervous system, the oral mucosa, and the skin. Moreover, 
CARD9-dependent functions have recently been indicated to modulate the develop-
ment of autoimmunity, inflammatory bowel diseases, and cancer. In this mini-review, 
we highlight the recent studies that have identified several novel functions of CARD9 in 
various disease contexts, and we summarize the contemporary understanding of the 
genetics and immunology of human CARD9 deficiency.
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inTRODUCTiOn
Innate recognition of microbes by pattern recognition receptors (PRRs) is a critical first step in 
the defense against infection. To activate antimicrobial immunity, PRRs must initiate intracellular 
signaling cascades which control cellular responses, such as cytokine production, phagocytosis, and 
assembly of microbial killing complexes. Many PRRs use signaling molecules and adaptor proteins 
that are shared with other members of the same PRR family. As a result, deficiency of a shared 
signaling or adaptor protein often results in immune dysfunctions that are more severe than a 
deficiency in a single receptor and can have profound consequences for the control of infections (1).
Pathogenic fungi are predominantly recognized by the C-type lectin receptor (CLR) and toll-
like receptor (TLR) families, of which many members couple to the signaling adaptor proteins 
CARD9 and MyD88, respectively, in order to activate their functions and initiate defense against 
fungal invasion (2). Although both CLRs and TLRs bind to and activate antifungal immune 
responses, the phenotypic consequences of human deficiencies in either of the two shared sign-
aling adaptors have demonstrated that CARD9 plays a specific, superior role in the control of 
fungal diseases in humans compared to that of MyD88. Indeed, patients with genetic deficiency 
in CARD9 exhibit a primary immunodeficiency disorder (PID) which manifests as an extreme 
susceptibility to fungal infections, but not bacterial, viral, or parasitic infections, and is the only 
PID described to date that specifically predisposes to fungal diseases without other infectious or 
non-infectious sequelae (3). In contrast, MyD88 deficiency results in the development of life-
threatening pyogenic bacterial infections without the spontaneous development of fungal disease 
(4). The highly specific susceptibility to fungi in CARD9-deficient patients further extends to 
FigURe 1 | CARD9-dependent signaling in response to (A) fungal ligands via Dectin-1, (B) muramyl-dipeptide derived from intracellular bacterial pathogens,  
or (C) viral DNA or RNA.
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the fungal species and organs affected, indicating that CARD9 
is required for organ-specific antifungal immune responses 
of which we are only now beginning to define. Furthermore, 
animal models and genome-wide analyses of human single-
nucleotide polymorphisms (SNPs) have indicated that CARD9 
may also function to promote immunity to other pathogens 
and contribute toward autoimmune and hyperinflammatory 
disorders. Thus, CARD9 is a multi-functional signaling protein 
involved in many aspects of the immune system.
In this review, we discuss recent research that has unveiled 
the many possible functional roles of CARD9, predominantly 
defined using animal models. Finally, we discuss the genetics of 
human CARD9 deficiency and highlight the critical role for this 
molecule in antifungal immune surveillance in humans.
THe MULTi-FUnCTiOnAL ROLeS OF 
CARD9
CARD9 is a Critical Activator of Antifungal 
immune Responses
Many of the prototypical PRRs that recognize common compo-
nents of fungal cell walls are members of the CLR family, and 
include Dectin-1, Dectin-2, Dectin-3, Mincle, and the Mannose 
Receptor (CD206). Many of these receptors initiate intracellular 
signaling cascades that are CARD9-dependent, the best studied 
of which is the Syk-dependent pathway downstream of Dectin-1 
(Figure 1A). In brief, ligation of Dectin-1 by β-glucan (the fungal 
ligand for this receptor) results in recruitment of Syk kinase and 
the formation of the CBM signalosome, composed of CARD9, 
BCL10, and MALT1 (5). Activation of CARD9 function requires 
Vav proteins, of which there are three isoforms (Vav1, Vav2, 
and Vav3). Deletion of Vav1-3 in mice results in a phenocopy 
of CARD9-deficiency, indicating that Vav-mediated activation of 
CARD9 is a critical step in the induction of protective antifungal 
immunity. In line with this, human VAV3 SNPs are enriched in 
patient cohorts with candidemia (6). Activated CARD9 then 
leads to the production of inflammatory mediators, such as IL-6, 
IL-12, GM-CSF, TNF, and IL-1β via the activation of NFκB and 
ERK, the latter of which occurs via a RASGRF1–H-Ras pathway 
(7). These CARD9-dependent signaling pathways are regulated 
by Rubicon, a protein best known for its functions in autophagy 
(8). Rubicon competitively binds to CARD9 which results in the 
disassembly of the CBM complex, thus switching off signaling 
and preventing excessive inflammatory responses. However, 
modulation of Rubicon expression levels using lentiviral vectors 
in mice demonstrated that a reduction in Rubicon expression 
could help promote fungal clearance and survival by enhancing 
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CARD9-dependent antifungal immune responses, at least in 
acute infection models (8). Compared to other PRR families, 
the molecular signaling events that occur upon CLR ligation are 
poorly defined. Yet, understanding these pathways will be critical 
to determine how iatrogenic interventions that manipulate these 
pathways affect vulnerable patients. For example, the recently 
introduced Syk inhibitors for hematological malignancies and 
graft-versus-host disease (9, 10), may predispose to the develop-
ment of dangerous invasive fungal infections in patient cohorts 
already at risk for these diseases.
Animals with a genetic deletion of Card9 are susceptible to 
challenge with a variety of fungal species, including Candida 
albicans, Aspergillus fumigatus, Cryptococcus neoformans, and 
some rarer dematiaceous fungi (11–14). In each of these models, 
Card9−/− mice generally exhibit reduced inflammatory cytokine 
production, which contributes to the inability to control fungal 
growth within infected organs. Protective antifungal cytokines 
that appear critically dependent on CARD9 function include 
IL-6, TNF, and IL-1β. In humans, CARD9 deficiency predisposes 
to a smaller range of pathogenic fungi (discussed below) indicat-
ing that CARD9-dependent functions in humans may be more 
context-dependent than in the mouse.
Despite the central position of CARD9 in the CLR signal-
ing pathway, ablation of CARD9 function does not result in 
complete abrogation of antifungal immune responses (in either 
mice or human), indicating that CARD9-dependent mecha-
nisms are required only for certain protective processes that may 
be specific to the cell type in question. Indeed, the dependency 
on CARD9 for NFκB activation has been shown to vary among 
different types of myeloid cells (7), including neutrophils, 
macrophages, and dendritic cells (DCs) (13). Neutrophils are 
the most important effector cell in the defense against systemic 
C. albicans infections, since neutropenia is a significant inde-
pendent risk factor for the development of and suffering worse 
outcome from these infections in humans, and neutrophil 
depletion significantly reduces survival to C. albicans challenge 
in mice (2, 15). Many intrinsic neutrophil functions, including 
phagocytosis, production of reactive oxygen species (ROS), and 
chemotaxis appear largely independent of CARD9 for a variety 
of fungal species, shown with ex vivo studies using human 
neutrophils (16–19). In contrast, for ROS-independent fungal 
killing, CARD9 is required for the killing of unopsonized yeast 
cells as part of a PI3Kγ-dependent pathway, whereas killing of 
opsonized C. albicans yeast largely requires FcRγ and PKC and 
is independent of CARD9 (20). These two distinct fungal killing 
pathways utilized by neutrophils helps to explain the observation 
that neutrophils isolated from CARD9-deficient patients exhibit a 
selective killing defect toward unopsonized yeast (18, 19). This 
defect may partly contribute toward the fungal central nervous 
system (CNS)-tropism observed in CARD9-deficient patients 
(see below), since opsonization is naturally low in the CNS and 
thus CARD9-dependent killing of unopsonized cells would 
be particularly critical at this site. However, human neutrophil 
killing against the invasive filamentous Candida forms observed 
in tissue appears intact, whether opsonized or unopsonized 
(19). In addition, we and others have shown that a critical func-
tion of CARD9 in antifungal defense is promoting neutrophil 
recruitment specifically into fungal-infected organs via CXC 
chemokine production in both mice and humans (19, 21), 
which appears to largely contribute toward the organ-specific 
manifestation of fungal diseases observed in CARD9-deficient 
humans.
In experimental C. albicans CNS infections in mice, CARD9 
promotes neutrophil recruitment in a fungal- and brain-specific 
manner (19). In this situation, CARD9 is required for the appro-
priate induction of CXC chemokines in the CNS by resident 
macrophages (i.e., microglia) and glia cells, as well as recruited 
neutrophils. Therefore, CARD9 controls local inflammatory 
chemokine production in addition to a neutrophil-intrinsic 
positive feedback chemotaxis loop in the brain (19). CARD9-
dependent production of neutrophil-attracting chemokines is 
also evident during pulmonary infection with A. fumigatus in 
mice (14), and we recently reported CARD9-deficient patients 
who developed extrapulmonary A. fumigatus infection that was 
associated with a lack of neutrophil accumulation at the infected 
site (21). Moreover, reduced production of CXC chemokines 
resulting in a lack of neutrophil recruitment has been described 
in chronically fungal-infected subcutaneous tissue in experimen-
tal phaeohyphomycosis models (22). Therefore, CARD9 appears 
to be a central regulator of neutrophil recruitment to specific 
organs during invasive fungal infection.
CARD9 and Anti-Bacterial immunity
Stimulation of Card9−/− myeloid cells with purified bacterial 
products has revealed that CARD9 is required for inflammatory 
cytokine production in response to specific bacterial stimuli. 
IL-6 production following stimulation with peptidoglycan or 
muramyl-dipeptide (MDP), predominant components of Gram- 
positive bacterial cell walls, is highly dependent on CARD9 
whereas responses to LPS are CARD9-independent (23). Recog-
nition of MDP is largely controlled by the intracellular NOD2 
receptor, to which CARD9 couples in order to drive activation 
of p38 and JNK kinases (Figure 1B), thus promoting immunity 
to intracellular bacterial pathogens including Listeria mono­
cytogenes (23) and Mycobacterium tuberculosis (24).
In addition to activating innate immune responses to intra-
cellular bacteria, other studies have indicated that CARD9 may 
be involved in the induction of adaptive immunity to these 
pathogens. Mouse T-cells specific for flagellin were shown to 
require Syk-CARD9 signaling for their activation, which was 
mechanistically linked to TLR5-dependent antigen presenta-
tion by CARD9-expressing DCs (25). Polarization to the Th17 
lineage also depends on CARD9 in the context of gastrointestinal 
(GI) bacterial infection (26), similar to what has been described 
for the generation of Th17 responses in the fungal-infected 
oral mucosa (27). Moreover, humoral immunity mediated by 
B-cells has also been shown to be affected by deletion of Card9, 
since bacterial-specific IgG production during GI infection is 
significantly reduced in Card9−/− animals (28). Thus, animal 
models have demonstrated that Card9 can play distinct protective 
roles in immunity to intracellular bacterial pathogens, however, 
the relevance of these functions in humans remains to be 
determined given that CARD9-deficient patients do not appear 
susceptible to bacterial infections.
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CARD9 and Antiviral immunity
Studies delineating the molecular pathways controlling IL-1β 
activation and secretion by myeloid cells in response to viral 
infection have identified CARD9 as a key regulator of these 
responses (Figure 1C). Following viral infection or transfec-
tion with foreign DNA, CARD9 directly interacts with Rad50, 
a cytosolic DNA sensor, and these CARD9-Rad50 complexes 
subsequently recruit BCL10 to promote IL-1β secretion. Using 
a vaccinia virus infection model, Card9−/− animals were shown 
to produce reduced levels of IL-1β following infection which 
negatively impacted the ability of these animals to generate 
an appropriate antiviral CD8+ T-cell response (29). CARD9 
is also required for immunity to retroviruses by transducing 
RIG-1-dependent signals via MAVS and BCL10 to activate 
NFκB and transcription of pro-IL-1β, which in turn is 
processed into active IL-1β by ASC-dependent activation of 
the inflammasome (30). As shown for antifungal immunity, 
Rubicon can also regulate these CARD9-dependent antiviral 
functions, since enhancing Rubicon expression levels was 
found to significantly skew host immunity in favor of pathogen 
resistance (8).
CARD9 and Autoimmunity
Recent studies have demonstrated potential novel roles of 
CARD9 in autoimmune diseases using animal models, provid-
ing interesting new insights into how this protein functions 
in organ-specific inflammation. During experimental uveitis, 
Mincle-mediated activation of CARD9 is required for the recruit-
ment of pathogenic Th1 and Th17  cells (31), and it was later 
shown that fungal antigens could exacerbate the development 
of this disease and this occurred via Dectin-2-CARD9 signal-
ing (32). In line with the critical role for CARD9 in neutrophil 
recruitment, Card9−/− animals showed reduced production of 
neutrophil-targeted chemokines, such as CXCL1, CXCL2, and 
CCL3, resulting in decreased accumulation of neutrophils to the 
arthritic joint (33). As a result, Card9−/− animals are protected 
from autoantibody-induced arthritis, and this protection was 
mapped to neutrophils using neutrophil-specific Card9-deficient 
mice (33). Population-based human studies have indicated that 
CARD9 genetic variation may modulate the risk of develop-
ment of inflammatory bowel diseases (IBD; discussed below), 
ankylosing spondylitis (34), IgA nephropathy (35), and primary 
sclerosing cholangitis (36), and more studies are required to 
determine the role of the CLR/CARD9 axis in organ-specific 
autoimmune disease development.
CARD9 and Cancer
CARD9-dependent signaling in tumor development and meta-
stasis has been revealed in several recent studies using animal 
models and cell lines. Patients with IBD are at risk for the deve-
lopment of colonic cancers. Human SNPs in CARD9 have been 
identified as risk factors for IBD by several GWAS-based studies 
(discussed below), and animal models have shown that CARD9 
promotes the production of pro-inflammatory cytokines IL-1β 
and IL-22 in the gut during active colitis, which in turn drives 
colonic tumor growth (37). Other work has additionally shown 
that metastasis of colonic tumor cells to the liver depends on 
CARD9 signaling. CARD9 is highly expressed by tumor-
infil trating macrophages and has been shown to be a critical 
modulator of the polarization of these cells toward a highly 
inflammatory metastatic-inducing phenotype (38).
In addition to colonic cancer, CARD9 signaling has also been 
implicated in the inappropriate activation of renal cell carcinoma 
(RCC) cells. Mutation affecting the tumor suppressor gene VHL 
(most often somatic, but occasionally involving germline cells) 
is a major hallmark of RCC, which in turn causes inappropri-
ate activation of NFκB and c-Jun. CARD9 is a mechanistic link 
between VHL inactivation and the activation of these inflamma-
tory transcription factors (39, 40). Direct interaction between 
CARD9 and VHL is required for C-terminal phosphorylation 
of CARD9 by the kinase CK2, which limits CARD9 activity and 
NFκB activation. Reducing CARD9 expression with a silencing 
RNA approach in VHL−/− cells lowered NFκB activity to wild-
type levels, and significantly reduced the tumorigenic potential 
of these cells (40). Similarly, the loss of VHL promotes an 
additional pro-inflammatory CARD9-dependent pathway that 
results in the activation of JNK signaling and c-Jun activity (39). 
Collectively, these studies provide the intriguing possibility that 
inappropriate CARD9 activation contributes to the development 
of certain cancers and may be a novel target of future therapies 
for these diseases.
THe geneTiCS AnD CLiniCAL 
SPeCTRUM OF HUMAn CARD9 
MUTATiOnS
Despite the wide range of CARD9-dependent functions iden-
tified in animal models and the potential influence of this protein 
in several disease scenarios, loss-of-function mutations in human 
CARD9 have unequivocally demonstrated the importance of 
CARD9 in antifungal immunity. Human CARD9 deficiency 
is characterized by the spontaneous development of fungal 
infections that predominantly localize to the oral mucosa, CNS, 
bone, and subcutaneous tissues, and often involves specific 
families of pathogenic fungi including Candida species (CNS, 
bone, and mucosal disease) and dark-walled molds and yeast-
like fungi (e.g., Aspergillus, Exophiala, and Phialophora) that 
localize to the CNS, skin, bone, and abdominal organs (3, 21, 
41–43). The underlying mechanisms that cause susceptibility to 
fungal diseases in CARD9-deficient patients is not well under-
stood, and could be related to the poor production of inflamma-
tory cytokines and chemokines in response to fungal agonists 
(13, 18, 19). Indeed, a cohort of French-Canadian CARD9-
deficient patients were successfully treated with recombinant 
GM-CSF therapy, which the authors show corrected defective 
GM-CSF responses and ERK signaling in CARD9-deficient 
myeloid cells (43), while another study used G-CSF therapy to 
correct defective IL-17 responses in a CARD9-deficient patient 
(44). These studies indicate that replacing cytokines that are 
classically associated with antifungal defense may be an appro-
priate therapy option for human CARD9 deficiency. However, 
we recently showed that these approaches may not be effective 
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for all patients which are potentially related to the variety of 
CARD9 mutations observed (see below). Our data indicated that 
although different CARD9 mutations disrupt GM-CSF produc-
tion by myeloid cells, the impact of these mutations on ERK 
activation varied with mutation and appeared to correlate with 
the efficacy of GM-CSF therapy in these patients (45). Thus, 
treatment options for human CARD9-deficiency are still limited, 
and further investigation into the mechanisms that cause fungal 
susceptibility in these patients is warranted. In addition, the 
organ- and fungal species-specific nature of CARD9-deficiency 
disease is also poorly understood. As discussed above, we and 
others have shown that defects in neutrophil recruitment are 
likely the major contributing factor toward the organ-specific 
nature of the disease, however, other contributing roles of 
tissue-resident macrophages, stromal cells, and/or additional 
functional deficits in recruited inflammatory cells remain to be 
fully explored.
Although many CARD9-deficient patients have similar cli-
nical presentations, there is diversity in the genetic mutations 
underlying the condition [see Ref. (3) for a table of all reported 
human CARD9 mutations]. More than 15 missense and non-
sense mutations in CARD9 have now been described in the 
coiled-coil and CARD domains, as well as the promoter region 
(3). Inactivation of both alleles appears to be necessary for the 
occurrence of disease, so the condition follows an autosomal 
recessive mode of inheritance. De novo variants in CARD9 have 
also been reported in patients with debilitating fungal infec-
tions of the eyes, bone, and skin (46, 47). Interestingly, although 
some of the reported CARD9 mutations have been identified in 
unrelated patients, there are instances where the same mutation 
does not give rise to a similar clinical phenotype (3). For exam-
ple, homozygosity for the Q298X mutation has been reported 
to give rise to Candida meningoencephalitis and deep derma-
tophytosis in different patients (41, 48), while patients with very 
similar clinical presentations can have mutations in different 
parts of the CARD9 gene (47). Therefore, it is currently unclear 
which mutations predispose to which clinical phenotypes and 
whether there is any overlap, and this will require more clinical 
descriptions of CARD9-deficient patients and further investiga-
tions into CARD9-dependent immune signaling and functions, 
especially in humans.
Like many other genes that are associated with Mendelian 
traits, human CARD9 is intolerant to sequence variation. 
To quantify gene-level intolerance to functional genetic varia-
tion, Petrovski et al. proposed a Residual Variation Intolerance 
Score (49). Of the nine CARD genes for which a score was 
calculated in that study, only three (CARD9, CARD10, and 
CARD11) had negative scores, suggesting low tolerance to func-
tional genetic variation. In fact, CARD9 had lower tolerance to 
variation than 82% of the 16,956 genes for which a score was 
calculated in the study.
In addition to deleterious mutations which predispose to 
fungal infection, there have been reports of genetic variants of 
CARD9 in humans that associate with autoimmune disease. The 
CARD9 single-nucleotide polymorphism S12N (rs4077515) 
was recently shown to be highly enriched in patients with aller-
gic bronchopulmonary aspergillosis, which the authors linked 
to RelB activation by this CARD9 variant that subsequently 
activated IL-5 production by alveolar macrophages and 
drove pathogenic eosinophil recruitment and Th2 responses 
within the lung (50). Another example is the CARD9 variant 
in which the C-terminal region is truncated (51, 52). One of 
these truncated variants of CARD9 (S12NΔ11 or CARD9Δ11) 
is strongly associated with protection against IBD, which is 
mechanistically linked to the inability of these variants to be 
activated by TRIM62, a ubiquitin ligase that is required for 
CARD9 activation and subsequent pro-inflammatory cytokine 
production. While the lack of TRIM62-mediated activation is 
protective in the context of inappropriate intestinal inflamma-
tion and may represent a target for therapeutic intervention 
in IBD (53), these mutations would be predicted to negatively 
affect antifungal immunity, since Trim62−/− animals are unable 
to control fungal growth and succumb to infection signifi-
cantly faster compared to their wild-type counterparts (52). 
Intriguingly, in human cell lines, CARD9Δ11 variants act in a 
dominant-negative fashion (52), raising the possibility of the 
existence of humans who may be heterozygous for dominant-
negative CARD9 mutations in the C-terminal region and 
yet may present with functional CARD9-deficiency. This 
possibility should be considered by clinicians looking for the 
underlying cause of an extreme fungal infection in an other-
wise immunocompetent patient.
While the CARD9Δ11 variant is protective in IBD, other 
lines of evidence suggest a role for CARD9 in the pathogenesis 
of the disease. Specifically, there are other CARD9 variants that 
are enriched in patient cohorts with IBD (51) indicating that 
dysregulated CARD9 function can have profound consequences 
for immune homeostasis in the gut. The CARD9 human SNP, 
S12N, is associated with increased CARD9 mRNA expression 
and IBD development (51, 54), but not fungemia (55), thus 
supporting the notion that CARD9-dependent functions in 
the immune system are context-dependent. However, many 
studies analyzing the functions of CARD9 in the context of 
GI inflammation have discovered links between the develop-
ment of GI disorders and fungal commensals, indicating that 
CARD9-dependent functions in innate fungal defense may 
also be important in gut-related diseases. For example, CARD9 
deficiency has been associated with an over-representation of 
fungi within the microbiota (56), and there have been reports 
of CARD9-deficient patients developing colitis caused by 
invasive intestinal infection with Candida glabrata (48), and 
most recently by the β-glucan-containing microalgae Prototheca 
zopfii (57). These studies suggest that, at least partially, CARD9 
may function to control fungal microbes in the gut and prevent 
infection-related disease in these tissues, which might explain 
the strong association between human CARD9 genetic variants 
and the development of IBD-related disorders.
COnCLUDing ReMARKS
The significance of CARD9 and its signaling partners in anti-
fungal defense has been an important realization for the field 
in the past two decades. A comprehensive understanding of the 
CARD9-dependent signaling pathways and their relevance for 
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disease processes will be required to (1) utilize CARD9 as a future 
therapeutic target and (2) prevent and treat possible side-effects 
of immune-based therapies for cancer and autoimmunity. In 
particular, the non-fungal-related functions of CARD9 warrant 
further study, especially to understand the relevance of these 
functions in humans who carry genetic variants of CARD9, 
which are currently only partially defined yet have the potential to 
significantly influence CARD9-dependent functions. The study 
of human CARD9 deficiency has yielded novel insights into 
how this adaptor signaling molecule functions to protect against 
invasive fungal diseases and, importantly, these findings point 
to potential new avenues for the development of immune-based 
treatments for invasive fungal infections, which represent a global 
clinical challenge.
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